Multiple-system atrophy (MSA) is a rare progressive, neurodegenerative
disease that is clinically characterised by autonomic
failure in addition to various features of parkinsonism, cerebellar
ataxia, and pyramidal dysfunction. Tomislav Babic, Natalia E.
Drosopoulou and Henry J. Riordan at Worldwide Clinical Trials
highlight salient issues related to clinical presentation and diagnosis,
biomarkers, and outcome measures in hopes of enhancing future
clinical trials in MSA.